Q: Would like your thoughts on this company,is their value here at this price,do you think the worst is over and is their a chance for a decent bounce off these lows thank you
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Hello,
I am down 67% on this stock. Would you suggest sitting tight until after the appeal in September?
Appreciate your thoughts.
I am down 67% on this stock. Would you suggest sitting tight until after the appeal in September?
Appreciate your thoughts.
Q: I thought that a drug had to be on the market for years before generics were allowed to enter the market. Help me understand what’s happening.
Q: Hi 5i Team,
Pls comment on Amarin Corp ‘s earning and give your outlook of this company. Share price dropped 7% at the time of writing.
I am holding a small position, buy more, hold or sell?
Thank you for your professional advice and help as always.
Pls comment on Amarin Corp ‘s earning and give your outlook of this company. Share price dropped 7% at the time of writing.
I am holding a small position, buy more, hold or sell?
Thank you for your professional advice and help as always.
Q: Any update on AMRN? Recently has pulled back to where it was in early November before the announcement of expanded use. Would you continue to hold?
Q: Hi 5i Team,
Today analyst at Oppenheimer issues a report which commented a very bearish take on Amarin
Corp stock , arguing it will fall to 7.00 within 18 months due to higher cost in sale. This resulted a 15% drop at time of writing.
I am holding this stock for a few months , should I hold , sell or buy more?
What is your take? Are you still positive on this stock?
Thank you for your professional advice and assistance as always.
arguing
Today analyst at Oppenheimer issues a report which commented a very bearish take on Amarin
Corp stock , arguing it will fall to 7.00 within 18 months due to higher cost in sale. This resulted a 15% drop at time of writing.
I am holding this stock for a few months , should I hold , sell or buy more?
What is your take? Are you still positive on this stock?
Thank you for your professional advice and assistance as always.
arguing
Q: Hi 5i team,
Back to AMRN. I thought they hit a home run yesterday with a unanimous (16 to 0) vote of the Advisory Committee to approve an expanded label use of Vascepa for treating various heart-related conditions, which should give them access to a much larger patient population base. However, the market is not so sure as the response is very muted at least so far today, and that may change. I took a small position to manage risk as I expected a big move one way or the other. I recognize this still has to go to the full FDA in a few weeks, but I understand that the FDA seldom overturns a strong endorsement of the AdCom. Am I missing something here in the muted market response?
Thanks again.
Dave
Back to AMRN. I thought they hit a home run yesterday with a unanimous (16 to 0) vote of the Advisory Committee to approve an expanded label use of Vascepa for treating various heart-related conditions, which should give them access to a much larger patient population base. However, the market is not so sure as the response is very muted at least so far today, and that may change. I took a small position to manage risk as I expected a big move one way or the other. I recognize this still has to go to the full FDA in a few weeks, but I understand that the FDA seldom overturns a strong endorsement of the AdCom. Am I missing something here in the muted market response?
Thanks again.
Dave
Q: FDA apparently has positive views on AMARIN's new drug Vascepa so approval for broad use seems likely; hence the recent pop. How much more upside does the stock have in the medium term.
Thanks for your insight.
Ian
Thanks for your insight.
Ian
Q: Hi 5i team,
This is a further question on healthcare and their binary outcomes on drug trials and approvals. I did buy MDT by the way based on its growth prospects and little or no dependence on drug approvals. This question is on AMRN and more generally the FDA approval process. AMRN has an upcoming date with the FDA on November 14th. From a business site, I quote “The Adcom review of the sNDA for Vascepa on its cardioprotective benefit is scheduled for November 14, 2019 with PDUFA planned for December 28, 2019”. What does that mean and how does one go about handicapping the odds of FDA approval or not? If this is largely a coin flip, then I will pass. If it is a progression towards likely approval, I may take a small position. I also understand that AMRN will be subject to a trading halt on Thursday while the review process is underway.
Thanks again for your insight into AMRN and the FDA approval process.
Dave
P.S. I notice that NXTC is down over 50% in the pre-market, a stock you mentioned in the FP for its crazy run last week. I thought tech stocks were volatile. They trade like utilities compared to drug stocks!
This is a further question on healthcare and their binary outcomes on drug trials and approvals. I did buy MDT by the way based on its growth prospects and little or no dependence on drug approvals. This question is on AMRN and more generally the FDA approval process. AMRN has an upcoming date with the FDA on November 14th. From a business site, I quote “The Adcom review of the sNDA for Vascepa on its cardioprotective benefit is scheduled for November 14, 2019 with PDUFA planned for December 28, 2019”. What does that mean and how does one go about handicapping the odds of FDA approval or not? If this is largely a coin flip, then I will pass. If it is a progression towards likely approval, I may take a small position. I also understand that AMRN will be subject to a trading halt on Thursday while the review process is underway.
Thanks again for your insight into AMRN and the FDA approval process.
Dave
P.S. I notice that NXTC is down over 50% in the pre-market, a stock you mentioned in the FP for its crazy run last week. I thought tech stocks were volatile. They trade like utilities compared to drug stocks!
Q: Could you discuss the implications of the recent news. Is this change the fundamentals significantly enough to warrant selling today?
Q: Have a half position in AMRN in my growth portfolio where I am very comfortable with risk as I am well diversified and conservative in the rest of my portfolios. Is the recent decrease due to a secondary offering an opportunity to increase my position?
Q: If one reviews the news releases of AMRN there is a litany of releases regarding numerous class action law suits emanating from a number of different law firms. Can you enlighten me as to why there are so many suits and so many law firms involved. Thanks for your great service.
Mike
Mike
Q: Hi gang
What are your thoughts on Amarin today? Any news in the last month or two? It's quite interesting to me on a personal level but as a stock I am on hold for now but may dabble depending on your answer. I can handle some risk.
Thanks as always for all you do.
What are your thoughts on Amarin today? Any news in the last month or two? It's quite interesting to me on a personal level but as a stock I am on hold for now but may dabble depending on your answer. I can handle some risk.
Thanks as always for all you do.
Q: Could we have an update on AMRN please, It was up nicely today. Thanks as always
Q: What are your thoughts on AMRN? Would you recommend buying at this time?
Q: On Saturday there was a press release regarding the results of a heart drug study and the share price of the company has bombed today. The results noted appeared positive to me however I am not an expert on the drug study details. Do you know why there is such a drastic adverse reaction to the Amarin stock price?
Q: Vascepa is already fda approved and they have 200 million in sales where is the risk or is this just a partial approval from the fda pending further study and on a scale of 1 to 10 how risky is it ten being the riskiest. dave
Q: Good morning folks. With some "fun money"..perhaps half a percent...would a swing trade within my TFSA be a good bet? Now or after next weeks report? Much thanks
Q: Hi !
Early in his WEBINAR presentation last week, Peter referred to a drug co, which sounded like "emera", at about 4.$
Can you tell me what it is ?
Many thanks,
JD
Early in his WEBINAR presentation last week, Peter referred to a drug co, which sounded like "emera", at about 4.$
Can you tell me what it is ?
Many thanks,
JD
Q: I have a question about Amarin.Can you provide comment on your view of Amarin as an investment from this point forward?